Compare Stocks → Pentagon contract could send this $2 AI stock soaring (From Behind the Markets) (Ad) Compare stocks and their fundamentals, performance, price, and technicals. Use this free stock comparison tool to evaluate companies based on their analyst ratings, book value, debt, dividend, MarketRank, news sentiment, price performance, profitability, and more. Enter up to ten stock symbols separated by a comma or space (ex. BAC, JPM, WFC, C, GS). Comparison Ideas Agriculture StocksAirline StocksApparel StocksArtificial Intelligence StocksAutomotive StocksBank StocksBitcoin StocksBlockchain StocksCanadian StocksCannabis StocksCasino StocksChatGPT StocksChinese StocksCloud Storage StocksCoronavirus Therapeutics StocksCryptocurrency StocksCybersecurity StocksDefense StocksDividend StocksDow 30 StocksEcommerce StocksElectric Vehicles StocksEnergy StocksEntertainment StockseSports StocksEV Charging StocksFertilizer StocksGold StocksGrocery StocksGrowth StocksHealthcare StocksHigh Dividend StocksHome Office StocksHotel StocksLarge Cap StocksLeisure StocksLithium StocksMagnificent Seven StocksMATANA StocksMega Cap StocksMeme StocksMetaverse StocksMid Cap StocksMining StocksMusic Industry StocksNanotechnology StocksNFT StocksOil StocksOutdoor Activities StocksPharmaceutical StocksRenewable Energy StocksRestaurant StocksRetail StocksSemiconductor StocksSocial Media StocksSolar StocksSpace StocksStay-At-Home StocksTechnology StocksTelecom StocksToy StocksUtility StocksVaccine StocksVideo Game StocksVirtual Reality StocksWallStreetBets Stocks Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare Share Comparison Share Comparison NASDAQ:ELDNNASDAQ:EVFMNASDAQ:NERVNASDAQ:ONTXOTCMKTS:RZLTD Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Stocks - Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeELDNEledon Pharmaceuticals$2.16+6.9%$1.79$1.07▼$2.95$53.59M0.8788,596 shs189,922 shsEVFMEvofem Biosciences$0.01-19.5%$0.02$0.01▼$3.75$691K-1.12790,899 shs1.92 million shsNERVMinerva Neurosciences$2.53-0.8%$3.77$2.26▼$13.49$17.69M0.21103,593 shs4,576 shsONTXOnconova Therapeutics$1.00-0.5%$0.82$0.55▼$1.45$20.90M1.3896,681 shs1.28 million shsRZLTDRezolute$3.54+3.2%$2.05$16.00▼$24.05$29.80M4.634,788 shs333,631 shs13 Stocks Institutional Investors Won't Stop BuyingWhich stocks are major institutional investors including hedge funds and endowments buying in today's market? Click the link below and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying up as quickly as they can.Get This Free ReportPrice PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceELDNEledon Pharmaceuticals+8.60%+23.17%+0.50%+18.82%-23.77%EVFMEvofem Biosciences+3.25%+6.00%-0.62%-51.82%-99.55%NERVMinerva Neurosciences+2.82%+5.37%-4.49%-67.10%+3.66%ONTXOnconova Therapeutics0.00%0.00%+14.68%+42.98%-8.69%RZLTDRezolute0.00%+27.04%+71.50%+250.00%+79.58%Don’t Miss Out on the AI Gold Rush That’s Just Getting Started (Ad)“Titan of Tech” Bets Big on Tiny AI Company He’s made as much as 3,250,000% in just three years on companies like Facebook, Airbnb, and PayPal… But our research shows his latest investment could be his most successful venture yet.See how you can invest alongside himMarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationELDNEledon Pharmaceuticals2.3137 of 5 stars3.53.00.00.01.11.71.3EVFMEvofem BiosciencesN/AN/AN/AN/AN/AN/AN/AN/ANERVMinerva Neurosciences3.0995 of 5 stars3.03.00.04.61.70.00.0ONTXOnconova Therapeutics0.9881 of 5 stars3.53.00.00.00.00.00.6RZLTDRezoluteN/AN/AN/AN/AN/AN/AN/AN/AAnalyst RatingsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceELDNEledon Pharmaceuticals3.00Buy$10.67393.83% UpsideEVFMEvofem Biosciences2.00HoldN/AN/ANERVMinerva Neurosciences2.00Hold$11.00334.78% UpsideONTXOnconova Therapeutics3.00Buy$11.001,005.19% UpsideRZLTDRezoluteN/AN/AN/AN/ACurrent Analyst RatingsLatest EVFM, ELDN, NERV, ONTX, and RZLTD Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails3/22/2024ELDNEledon PharmaceuticalsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$13.002/27/2024NERVMinerva NeurosciencesHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingNeutral ➝ Neutral$11.00(Data available from 4/23/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookELDNEledon PharmaceuticalsN/AN/AN/AN/A$3.45 per shareN/AEVFMEvofem Biosciences$18.22M0.04$1.28 per share0.01($2.64) per share0.00NERVMinerva NeurosciencesN/AN/AN/AN/A($4.07) per shareN/AONTXOnconova Therapeutics$230K90.88N/AN/A$1.35 per share0.74RZLTDRezoluteN/AN/AN/AN/A$1.24 per shareN/AProfitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateELDNEledon Pharmaceuticals-$40.33M-$1.79N/AN/AN/AN/A-46.15%-43.10%5/9/2024 (Estimated)EVFMEvofem Biosciences$52.98M-$7.62N/A∞N/A290.81%-90.20%331.20%4/26/2024 (Estimated)NERVMinerva Neurosciences-$30M-$4.65N/AN/AN/AN/AN/A-50.27%5/20/2024 (Estimated)ONTXOnconova Therapeutics-$18.96M-$0.91N/AN/AN/A-8,930.97%-95.43%-61.19%5/20/2024 (Estimated)RZLTDRezolute-$20.33MN/A0.00∞N/AN/A-153.46%-111.71%N/ALatest EVFM, ELDN, NERV, ONTX, and RZLTD EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails3/28/2024Q4 2023ELDNEledon Pharmaceuticals-$0.38-$0.29+$0.09-$0.29N/AN/A3/27/2024Q4 2023EVFMEvofem BiosciencesN/A-$0.44-$0.44-$0.44N/A$4.84 million2/22/2024Q4 2023NERVMinerva Neurosciences-$0.88-$1.19-$0.31-$1.19N/AN/ADividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthELDNEledon PharmaceuticalsN/AN/AN/AN/AN/AEVFMEvofem BiosciencesN/AN/AN/AN/AN/ANERVMinerva NeurosciencesN/AN/AN/AN/AN/AONTXOnconova TherapeuticsN/AN/AN/AN/AN/ARZLTDRezoluteN/AN/AN/AN/AN/ADebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioELDNEledon PharmaceuticalsN/A14.4114.41EVFMEvofem BiosciencesN/A0.130.10NERVMinerva NeurosciencesN/A12.5712.58ONTXOnconova TherapeuticsN/A2.792.79RZLTDRezoluteN/A3.263.26OwnershipInstitutional OwnershipCompanyInstitutional OwnershipELDNEledon Pharmaceuticals56.77%EVFMEvofem Biosciences0.22%NERVMinerva Neurosciences34.56%ONTXOnconova Therapeutics7.95%RZLTDRezoluteN/AInsider OwnershipCompanyInsider OwnershipELDNEledon Pharmaceuticals19.40%EVFMEvofem Biosciences0.21%NERVMinerva Neurosciences6.40%ONTXOnconova Therapeutics3.30%RZLTDRezolute4.60%MiscellaneousCompanyEmployeesShares OutstandingFree FloatOptionableELDNEledon Pharmaceuticals1724.81 million20.00 millionOptionableEVFMEvofem Biosciences3553.96 million53.85 millionNot OptionableNERVMinerva Neurosciences96.99 million6.55 millionNot OptionableONTXOnconova Therapeutics1621.00 million20.31 millionOptionableRZLTDRezolute238.42 millionN/ANot OptionableEVFM, ELDN, NERV, ONTX, and RZLTD HeadlinesSourceHeadlineAmerica/Resolute Time zone • Current Time in Resoluteprokerala.com - November 11 at 10:42 PMRezolute (RZLT) Earnings Dates & Reportsinvesting.com - November 9 at 8:09 AMXilio Development Inc (XLO)investing.com - September 3 at 8:34 PMSystems Ltd.forbes.com - August 9 at 6:47 PMStonegate Healthcare Partners Announces Publishing of a Thematic Report - Beyond VEGF: Therapies Revolutionizing Diabetic Eye Diseasebenzinga.com - June 1 at 3:38 PMAnalysts Are Bullish on These Healthcare Stocks: Rezolute (RZLT), Jazz Pharmaceuticals (JAZZ)markets.businessinsider.com - May 15 at 7:36 AMRezolute, Inc.: Rezolute Reports Third Quarter Fiscal 2023 Results and Highlights Company Progressfinanznachrichten.de - May 12 at 4:09 AMRezolute Reports Third Quarter Fiscal 2023 Results and Highlights Company Progressfinance.yahoo.com - May 11 at 6:07 PMGreat news for Rezolute, Inc. (NASDAQ:RZLT): Insiders acquired stock in large numbers last yearfinance.yahoo.com - April 25 at 9:16 AMRezolute (RZLT) Gets a Buy from H.C. Wainwrightmarkets.businessinsider.com - March 28 at 8:47 AMRezolute, Inc.: Rezolute Reports Second Quarter Fiscal 2023 Results and Highlights Company Progressfinanznachrichten.de - February 12 at 7:31 AMRezolute Reports Second Quarter Fiscal 2023 Results and Highlights Company Progressfinance.yahoo.com - February 10 at 6:54 PMXeris Biopharma Holdings Stock (NASDAQ:XERS), Quotes and News Summarybenzinga.com - February 7 at 7:20 AMAfter losing 37% in the past year, Rezolute, Inc. (NASDAQ:RZLT) institutional owners must be relieved by the recent gainfinance.yahoo.com - February 2 at 11:06 AMAnalysts Offer Insights on Healthcare Companies: Globus Medical (GMED) and Rezolute (RZLT)markets.businessinsider.com - November 10 at 1:53 AMRezolute to Present at the Jefferies London Healthcare Conferencetechnews.tmcnet.com - November 1 at 8:59 AMNew MarketBeat Followers Over TimeMedia Sentiment Over TimeCompany DescriptionsEledon PharmaceuticalsNASDAQ:ELDNEledon Pharmaceuticals, Inc. operates as a clinical stage biotechnology company. The company uses its immunology expertise in targeting the CD40 Ligand (CD40L, also called CD154) pathway to develop therapies to protect transplanted organs and prevent rejection, and to treat amyotrophic lateral sclerosis (ALS). The company's lead compound in development is tegoprubart, an anti-CD40L antibody with high affinity for CD40 Ligand, a biological target with therapeutic potential. It has a collaboration agreement with eGenesis, Inc. The company was formerly known as Novus Therapeutics, Inc. and changed its name to Eledon Pharmaceuticals, Inc. in January 2021. Eledon Pharmaceuticals, Inc. is headquartered in Irvine, California.Evofem BiosciencesNASDAQ:EVFMEvofem Biosciences, Inc., a biopharmaceutical company, develops and commercializes various products to address unmet needs in women's sexual and reproductive health. Its commercial product is Phexxi, a vaginal gel for the prevention of pregnancy. The company is also involved in the development of EVO100 for the prevention of chlamydia and gonorrhea in Women; and EVO200 for the prevention of recurrent bacterial vaginosis. Evofem Biosciences, Inc. is headquartered in San Diego, California.Minerva NeurosciencesNASDAQ:NERVMinerva Neurosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of product candidates for the treatment of central nervous system diseases. Its lead product candidate is roluperidone (MIN-101) for the treatment of negative symptoms in patients with schizophrenia, currently submitted an New Drug Application (NDA); and MIN-301, a soluble recombinant form of the neuregulin-1b1 protein for the treatment of Parkinson's disease and other neurodegenerative disorders. The company has a license agreement with Mitsubishi Tanabe Pharma Corporation to develop, sell, and import roluperidone globally excluding Asia. Minerva Neurosciences, Inc. was incorporated in 2007 and is based in Burlington, Massachusetts.Onconova TherapeuticsNASDAQ:ONTXOnconova Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing novel products to treat cancer in the United States. It has two clinical-stage programs, including narazaciclib, a multi-targeted kinase inhibitor that is in Phase I study for solid tumors, as well as hematological malignancies as a single agent or in combination with other anti-cancer therapies; and oral rigosertib alone or in combination with PD-1 inhibitor, which is in Phase I/IIa study for the treatment of progressive K-Ras mutated non-small cell lung cancer. The company also conducting a Phase II investigator-initiated study with rigosertib monotherapy in patients with advanced/metastatic squamous cell carcinoma associated with recessive dystrophic epidermolysis bullosa. It has a license and collaboration agreement with HanX Biopharmaceuticals, Inc. for the development, registration, and commercialization of narazaciclib in China. Onconova Therapeutics, Inc. was incorporated in 1998 and is headquartered in Newtown, Pennsylvania.RezoluteOTCMKTS:RZLTDRezolute, Inc., a clinical stage biopharmaceutical company, develops therapies for rare and metabolic diseases in the United States. The company's lead product candidate is RZ358, a human monoclonal antibody that is in Phase 2b clinical trial for the treatment of congenital hyperinsulinism, an ultra-rare pediatric genetic disorder. It also develops RZ402, a small molecule plasma kallikrein inhibitor, which is in preclinical stage for the treatment of diabetic macular edema. The company was formerly known as AntriaBio, Inc. and changed its name to Rezolute, Inc. in December 2017. Rezolute, Inc. was founded in 2010 and is headquartered in Redwood City, California. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.